human trail (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
90
Structured Review
R&D Systems
human trail
Human Trail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+expression/Recombinant+Human+TRAIL%2FTNFSF10+(E%2E+coli-expressed)+Protein/pm25188024-68-2-23
Average 90 stars, based on 38 article reviews
Human Trail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+expression/Recombinant+Human+TRAIL%2FTNFSF10+(E%2E+coli-expressed)+Protein/pm25188024-68-2-23
Average 90 stars, based on 38 article reviews
human trail - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Recombinant:Article Title: Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model Article Snippet: .. The cells were treated with the recombinant Article Title: Tumour necrosis factor-related apoptosis-inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro. Article Snippet: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is an apoptosis-inducing cytokine that shows potential therapeutic value for human neoplasms, and is effective in some canine tumors; however, its potential for killing canine hemangiosarcoma (HSA) cells is unknown.. Thus, we evaluated the proapoptotic effect of TRAIL in nine canine HSA cell lines.. Cells (JuA1, JuB2, JuB2-1, JuB4, Re11, Re12, Re21, Ud2, and Ud6) were cultured with three recombinant human TRAILs (rhTRAILs): TRAIL-TEC derived from Escherichia coli, TRAIL-TL derived from mammalian cells, and izTRAIL containing an isoleucine-zippered structure that facilitates trimerization. Multiple Displacement Amplification:Article Title: Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model Article Snippet: .. The cells were treated with the recombinant other:Article Title: TLR3 Ligand Poly(I:C) Exerts Distinct Actions in Synovial Fibroblasts When Delivered by Extracellular Vesicles. Article Snippet: SFs were directly stimulated with HMW Poly(I:C) (20 pg/ml to 20 μg/ml, InvivoGen, # tlrl-pic-5) or were transfected with HMW Poly(I:C) (0.02–1 μg/ml, InvivoGen, # tlrl-pic-5) using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Incubation:Article Title: Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure. Article Snippet: Acute liver failure (ALF) is a life-threatening disease with a high mortality rate.. There is an urgent need to develop new drugs with high efficacy and low toxicity.. In this study, we produced a pharmaceutical-grade soluble death receptor 5 (sDR5)-Fc fusion protein for treating ALF and evaluated the pharmacology, safety, pharmacokinetics, efficacy, and mechanisms of sDR5-Fc in mice, rats, and cynomolgus monkeys. sDR5-Fc bound with high affinity to both human and monkey tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) effectively blocked TRAIL-induced apoptosis in vitro and significantly ameliorated ALF induced by concanavalin A (Con A) in mice. |